Skip to main content

Cepheid Reports Revenue Hike, Increased Losses for Q2

NEW YORK, July 15-Cepheid today reported increased losses and a steep hike in revenues for the second quarter of 2002. 


For the three months ended June 30, 2002, revenues were $3.2 million, up from 2 million for the same quarter in 2001. Net losses were $5.5 million (21 cents per share) for the quarter, up from $4.1 million (16 cents per share) from the same quarter last year.


The company attributed its increased losses to R&D spending for its GeneXpert system. Cepheid opened a new California manufacturing center in June, and hopes to have that system in production by the end of the year.


Cepheid is being considered for a  contract by the United States Postal Service to install DNA-detection systems in its mail sorting facilities nationwide, an arrangement that could bring the company $25 million to $40 million in 2003, company representatives said.


The USPS plans to award the contract by the end of September 2002.


Cepheid executives said in a conference call that the company's directors planned to expand international sales. The company also announced an agreement with MedProbe to act as Cepheid's exclusive distributor in Norway, Sweden, Denmark, Finland and Iceland.


Cepheid said it had about $16 million in the bank. "We're in pretty good shape," said CEO John Bishop.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.